Aptamer Conjugated RNA/DNA Hybrid Nanostructures Designed for Efficient Regulation of Blood Coagulation

Cracking the Code: Enhancing Molecular Tools for Progress in Nanobiotechnology

“…30,32−35 Exploiting this trait, NANPs can be envisioned for a broad range of extracellular applications. To enhance the efficacy and safety profiles of existing anticoagulants, Afonin's team developed and tested a dynamic platform utilizing RNA− DNA fibers 36 that are encoded for efficient and reversible control of blood coagulation 37,38 (Figure 4A). These nucleic acid nanodevices are immunoquiescent and incorporate multiple thrombin-binding aptamers (e.g., G-quadruplexbased NU172 aptamers), significantly increasing their molecular weight, extending blood stability, and prolonging the retention time of anticoagulants in vivo.…”

“…NANPs present enormous potential for biomedical applications owing to their programmable nature, compatibility with biological systems, consistent performance across batches, and precise control over functionalization with therapeutic nucleic acids. , With a negatively charged backbone, NANPs exhibit immunoquiescent properties as they cannot enter cells directly, requiring carriers for cell entry. ,− Exploiting this trait, NANPs can be envisioned for a broad range of extracellular applications. To enhance the efficacy and safety profiles of existing anticoagulants, Afonin’s team developed and tested a dynamic platform utilizing RNA–DNA fibers that are encoded for efficient and reversible control of blood coagulation , (Figure A). These nucleic acid nanodevices are immunoquiescent and incorporate multiple thrombin-binding aptamers (e .g.…”